Can Ki-67 immunohistochemistry marker differentiate mycosis fungoides from cutaneous lichen planus?

Authors

  • Mazaher Ramezani Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Kambiz Kamyab Hesari Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Negar Ramezanizoorab Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Masoud Sadeghi Department of Biology, Science and Research Branch, Islamic Azad University, Tehran 1416753955, Iran
  • Mansour Rezaei Array (unauthenticated)
  • Sedigheh Khazaei Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

DOI:

https://doi.org/10.66344/jpad.v32i4.2019

Abstract

Objective The purpose of this study was to evaluate the immunohistochemical expression of Ki-67 marker in Mycosis Fungoides (MF) and Lichen Planus (LP) lesions.

 

Methods This cross-sectional analytical study included patients undergoing skin biopsy with their first clinical and pathologic diagnosis of MF and cutaneous LP by Ki-67 immunohistochemistry (IHC). Sixty-two patients with cutaneous LP and MF were studied in two groups of 39 and 23 patients, respectively. Linear regression was used for the possible correlation between age and Ki-67 index (%) in both LP and MF patients.

 

Results The results of this study found that Ki-67 was expressed in 100% of both MF and LP lesions, and no significant correlation was found between Ki-67 and either of the two types of diseases (p=0.606). The results of this study also showed that expression of Ki-67 marker was more than 25% in both types of diseases in 70% of the population, which seems not to be directly related to malignancy.

 

Conclusion IHC with proliferative marker Ki-67 is not a valuable technique for differentiating cutaneous LP from MF lesions alone.

 

References

1. Omal P, Jacob V, Prathap A, Thomas NG. Prevalence of oral, skin, and oral and skin lesions of lichen planus in patients visiting a dental school in southern India. Indian J Dermatol. 2012;57(2):107-9.

2. Gupta S, Jawanda MK. Oral Lichen Planus: An Update on Etiology, Pathogenesis, Clinical Presentation, Diagnosis and Management. Indian J Dermatol. 2015;60(3): 222-9.

3. Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015;1(3):140-9.

4. Okpala IC, Akinboro AO, Ezejoifor IO, Onunu AN, Okwara BU. Metabolic Syndrome and Dyslipidemia among Nigerians with Lichen Planus: A Cross-Sectional Study. Indian J Dermatol. 2019;64(4):303-10.

5. Nevile BW, Damm DD, Allen CM, Jerry EB. Oral and maxillofacial pathology. 2nd ed. Pensylvania wes philadephia, editor. W.B. Saundres Company; 2009. pp. 782–788.

6. Schwager Z, Stern M, Cohen J, Femia A. Clinical epidemiology and treatment of lichen planus: A retrospective review of 2 tertiary care centers. J Am Acad Dermatol. 2019;81(6):1397-9.

7. Kiran MS, Vidya S, Aswal GS, Kumar V, Rai V. Systemic and Topical Steroids in the Management of Oral Mucosal Lesions. J Pharm Bioallied Sci. 2017;9(Suppl 1):S1-S3.

8. Lozada-Nur F, Miranda C. Oral lichen planus: topical and systemic therapy. Semin Cutan Med Surg. 1997;16(4):295-300.

9. Thongprasom K, Dhanuthai K. Steriods in the treatment of lichen planus: A review. J Oral Sci. 2008;50(4):377-385.

10. Vaidya T, Badri T. Mycosis Fungoides. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.

11. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767-71.

12. Cerroni L, Fink-Puches R, Bäck B, Kerl H. Follicular Mucinosis: A Critical Reappraisal of Clinicopathologic Features and Association With Mycosis Fungoides and Sézary Syndrome. Arch Dermatol. 2002;138(2):182-9.

13. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-16;quiz 221-2.

14. Whittaker SJ. Cutaneous lymphoma and lymphocytic infiltrates. 8th ed. In: Burns, T. Breathnach, S. Cox, N. Griffiths C (eds.)., editor. Wiley-Blackwell; 2010.

15. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-63.

16. Reddy K., Bhawan J. Histologic mimickers of mycosis fungoides: a review. J Cutan Pathol. 2007;34(7):519-25.

17. Kelati A, Gallouj S, Tahiri L, Harmouche T, Mernissi FZ. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. Int J Womens Dermatol. 2017;3(2):100-6.

18. Arafah M, Zaidi SN, Kfoury HK, Al Rikabi A, Al Ghamdi K. The Histological Spectrum of Early Mycosis Fungoides: A Study of 58 Saudi Arab patients. Oman Med J. 2012;27(2):134-9.

19. Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator. Clin Dermatol. 2019;37(3):255-67.

20. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol. 2002;47(6):914-8.

21. Sajjan V, Chandela M, Pandit AM, Manjunathswamy B. Mycosis fungoides: The great imitator. Our Dermatol Online. 2015;6(1):76-9.

22. Litvinov IV, Netchiporouk E, Cordeiro B, Doré MA, Moreau L, Pehr K, et al. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL). Clin Cancer Res. 2015;21(12):2820-9.

23. Trager MH, Geskin LJ. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma. G Ital Dermatol Venereol. 2019;154(6):681-95.

24. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e1-17;quiz 240-2.

25. Fonatsch C, Duchrow M, Rieder H, Schlüter C, Gerdes J. Assignment of the human Ki-67 gene (MKI67)to 10q25-qter. Genomics. 1991;11(2):476-7.

26. Apte SS. Ki-67 monoclonal antibody (MAb) reacts with a proliferation associated nuclear antigen in the rabbit Oryctolagus cuniculus. Histochemistry. 1990;94(2):201-4.

27. Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Llères D, et al. The cell proliferation antigen Ki-67 organises heterochromatin. Elife. 2016;5:e13722.

28. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki‐67 antibody in HL‐60 cells. Cell Prolif. 1992;25(1):31-40.

29. Humayun S, Prasad VR. Expression of p53 protein and ki-67 antigen in oral premalignant lesions and oral squamous cell carcinomas: An immunohistochemical study. Natl J Maxillofac Surg. 2011;2(1):38-46.

30. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol. 2000;182(3):311-22.

31. Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol. 2010;4:15-34.

32. Xu L, Liu YH, Ye JM, Zhao JX, Duan XN, Zhang LB, et al. Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer. Zhonghua Wai Ke Za Zhi. 2010;48(6):450-3.

33. Kanavaros P, Bai M, Stefanaki K, Poussias G, Rontogianni D, Zioga E, et al. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Histol Histopathol. 2001;16(2):377-86.

34. Jankowska-Konsur A, Kobierzycki C, Reich A, Grzegrzolka J, Bieniek A, Dziegiel P. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides. Anticancer Res. 2016;36(1):189-97.

35. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 Expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33(12):1860-8.

36. Gambichler T, Bischoff S, Bechara FG, Altmeyer P, Kreuter A. Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders. J Dermatol Sci. 2008;49(2):125-32.

37. Soini Y, Kamel D, Pääkkö P, Lehto VP, Oikarinen A, Vähäkangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol. 1994;131(4):514-20.

38. Nickoloff BJ, Griffiths CEM. Intraepidermal but not dermal T lymphocytes are positive for a cell-cycle - Associated antigen (Ki-67) in mycosis fungoides. Am J Pathol. 1990;136(2):261-66.

39. Vinogradova IuE, Iliushkina EA, Kaplanskaia IB, Lutsenko IN, Zybunova EE, Kremenetskaia AM, et al. Diagnosis and treatment of skin T-cell lymphoma undergoing transformation in lymphosarcoma. Ter Arkh. 2009;81(7):57-61.

40. Bittencourt AL, Barbosa HS, Vieira MDG, Farr L. Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: Clinical, histological and immunohistochemical features of 52 cases. Acta Oncol. 2009;48(4):598-604.

41. Bittencourt AL, Mota K, Oliveira RF, Farré L. A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol. 2009;31(8): 834-7.

Downloads

Published

08.12.2022

Issue

Vol. 32 No. 4 (2022): October - December

Section

Original Articles

License

Copyright (c) 2022 Mazaher Ramezani, Kambiz Kamyab Hesari, Negar Ramezanizoorab, Masoud Sadeghi, Mansour Rezaei, Sedigheh Khazaei

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

How to Cite

1.
Can Ki-67 immunohistochemistry marker differentiate mycosis fungoides from cutaneous lichen planus?. J Pak Assoc Dermatol [Internet]. 2022 Dec. 8 [cited 2026 Jul. 27];32(4):676-82. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2019